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INTRODUCTION
During recovery from an intracranial procedure, smooth emer-
gence from general anesthesia with hemodynamic stability is 
a major concern for the anesthesiologist. Airway reflex and 
systemic hypertension during recovery may lead to cerebral 
edema or intracranial hemorrhage.1,2 Furthermore, rapid recov-
ery from general anesthesia is imperative in aiding early de-
tection of potential intracranial complications and neurologic 
deficits. 
A variety of strategies have been proposed for rapid and 
smooth emergence from general anesthesia.3-8 Remifentanil is 
an ultra-short-acting opioid and is conventionally used as an 
adjuvant agent in general anesthesia. Previous studies have 
shown that remifentanil prevents airway response and detri-
mental hemodynamic changes without a significant increase 
in recovery time.6,9,10 However, in neurosurgical patients, possi-
ble respiratory depression and related hypercapnia may be of 
Comparison of Dexmedetomidine and Remifentanil 
on Airway Reflex and Hemodynamic Changes during 
Recovery after Craniotomy 
Hyunzu Kim1, Kyeong Tae Min2,3, Jeong Rim Lee2,3, Sang Hee Ha2,  
Woo Kyung Lee2, Jae Hee Seo2, and Seung Ho Choi2,3
1Department of Anesthesiology and Pain Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul;
2Department of Anesthesiology and Pain Medicine and 3Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Purpose: During emergence from anesthesia for a craniotomy, maintenance of hemodynamic stability and prompt evaluation of 
neurological status is mandatory. The aim of this prospective, randomized, double-blind study was to compare the effects of dex-
medetomidine and remifentanil on airway reflex and hemodynamic change in patients undergoing craniotomy. 
Materials and Methods: Seventy-four patients undergoing clipping of unruptured cerebral aneurysm were recruited. In the dex-
medetomidine group, patients were administered dexmedetomidine (0.5 μg/kg) for 5 minutes, while the patients of the remifent-
anil group were administered remifentanil with an effect site concentration of 1.5 ng/mL until endotracheal extubation. The inci-
dence and severity of cough and hemodynamic variables were measured during the recovery period. Hemodynamic variables, 
respiration rate, and sedation scale were measured after extubation and in the post-anesthetic care unit (PACU).  
Results: The incidence of grade 2 and 3 cough at the point of extubation was 62.5% in the dexmedetomidine group and 53.1% in 
the remifentanil group (p=0.39). Mean arterial pressure (p=0.01) at admission to the PACU and heart rate (p=0.04 and 0.01, re-
spectively) at admission and at 10 minutes in the PACU were significantly lower in the dexmedetomidine group. Respiration rate 
was significantly lower in the remifentanil group at 2 minutes (p<0.01) and 5 minutes (p<0.01) after extubation.  
Conclusion: We concluded that a single bolus of dexmedetomidine (0.5 μg/kg) and remifentanil infusion have equal effective-
ness in attenuating coughing and hemodynamic changes in patients undergoing cerebral aneurysm clipping; however, dexme-
detomidine leads to better preservation of respiration.
Key Words:  Anesthesia recovery period, craniotomy, dexmedetomidine, remifentanil 
Yonsei Med J 2016 Jul;57(4):980-986
http://dx.doi.org/10.3349/ymj.2016.57.4.980
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: April 27, 2015   Revised: October 27, 2015
Accepted: October 28, 2015
Corresponding author: Dr. Seung Ho Choi, Department of Anesthesiology and 
Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College 
of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-2420, Fax: 82-2-2227-7897, E-mail: csho99@yuhs.ac
Preliminary results of the study were presented at the European Society of Anaes-
thesiology (ESA) Euroanaesthesia, 9–12 June 2012, Paris.
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2016
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
981http://dx.doi.org/10.3349/ymj.2016.57.4.980
Hyunzu Kim, et al.
concern when maintaining remifentanil target controlled infu-
sion (TCI) during the recovery period from general anesthesia. 
Dexmedetomidine is a potent, alpha 2-selective adrenocep-
tor agonist that causes sympatholysis, sedation, and analgesia 
without inhibiting respiration.11,12 Several studies have report-
ed that dexmedetomidine reduced hypertension and tachy-
cardia in patients undergoing neurosurgery.13,14 To the best of 
our knowledge, there have only been limited studies that have 
compared recovery profiles between a single dose of dexme-
detomidine and remifentanil TCI in neurosurgical patients.15,16
Therefore, we hypothesized that a single dose of dexmedeto-
midine can be more effective than remifentanil in attenuating 
airway reflexes and hemodynamic changes during the recovery 
period. The purpose of this prospective, randomized, case-
controlled study was to compare the effects of dexmedetomi-
dine and remifentanil on airway reflexes and hemodynamic 
changes during the recovery period in patients undergoing cra-
niotomy. 
MATERIALS AND METHODS
After obtaining approval from the Severance Hospital Institu-
tional Review Board (ref: 1-2011-0019), the study was regis-
tered at ClinicalTrials.gov (ref: NCT01365923). Written informed 
consent was obtained from all patients. Seventy-four patients, 
who were 20–70 years old, American Society of Anesthesiolo-
gists class I–II, and scheduled for clipping of an unruptured 
cerebral aneurysm (Modified Hunt and Hess Clinical grade 0), 
were prospectively enrolled in this study. Patients with respi-
ratory disease, advanced heart block, or uncontrolled hyper-
tension were excluded from the study. Patients were randomly 
allocated to one of two groups, the dexmedetomidine group or 
the remifentanil group, using an Excel®-generated randomiza-
tion table.
No patients were premedicated on arrival to the operating 
room. Patients were monitored via electrocardiography, pulse 
oximetry, non-invasive blood pressure, and capnography. Gen-
eral anesthesia was induced with propofol 1.5 mg/kg and 
remifentanil at an effect site concentration (Ce) of 4 ng/mL. 
The remifentanil infusion rate was controlled using a com-
mercial TCI system (Orchestra Base Primea, Fresenius Vial, 
Brezins, France) incorporating Minto’s pharmacokinetic mod-
el.17 After rocuronium 0.6 mg/kg was given intravenously, pa-
tients were intubated using an endotracheal tube with an in-
ternal diameter of 7.5 mm (for males) or 6.5 mm (for females). 
A cuff was inflated to maintain pressure between 20–25 cm 
H2O measured using a manometer (Hi-LoTM Hand Pressure 
Gauge, VBM Medizintechnik GmbH, Sulz am Neckar, Germa-
ny). A 20-G catheter was inserted in the radial artery to moni-
tor arterial blood pressure and arterial blood gas. A forced-air 
warming system (Bair-HuggerTM, Augustine-Medical, Eden 
Prairie, MN, USA) was applied throughout surgery to maintain 
the body temperature at 36.0–37.0°C.
Anesthesia was maintained with 0.6–1 minimum alveolar 
concentration (MAC) end-tidal concentration of sevoflurane 
in 50% oxygen/air mixture by using the Bispectral Index (BIS 
VISTA Monitoring System Inc., Norwood, MA, USA) to main-
tain a target BIS of 45–55. The remifentanil Ce was adjusted to 
sustain a mean arterial pressure (MAP) and heart rate within 
20% of preoperative resting values. All patients were positioned 
to optimize cerebral venous drainage, and mechanical ventila-
tion was adjusted to maintain PaCO2 35–40 mm Hg, confirmed 
during the operation via arterial blood gas analysis.
Ten minutes before the end of each surgery, sevoflurane 
was titrated to 0.6 MAC, and remifentanil was titrated to a Ce 
of 1.5 ng/mL in both groups. In the dexmedetomidine group, 
0.5 μg/kg dexmedetomidine was infused for 5 minutes. After 
the termination of dexmedetomidine administration, a nurse, 
who concealed the group from the investigator, switched a sy-
ringe of remifentanil to normal saline. Patients in the two groups 
received continuous infusion of remifentanil or normal saline 
at a Ce of 1.5 ng/mL until extubation. In both groups, after all 
surgical procedures were finished, sevoflurane and air-flow 
were discontinued, and oxygen flow was increased to 10 L/
min. Another anesthesiologist, blinded to the randomization, 
performed the remaining anesthetic recovery processes and 
collected all data. Ramosetron 0.3 mg was administered for 
the prevention of postoperative nausea and vomiting (PONV). 
Respiration was assisted by manual ventilation after confirm-
ing neuromuscular function via the train-of-four response. If 
patients opened their eyes in response to a verbal request and 
their respiration was adequate, the trachea was extubated af-
ter cuff deflation. In both groups, the blinded syringe of remi-
fentanil or normal saline was discontinued immediately after 
extubation. Patients in both groups were monitored while re-
ceiving 100% oxygen for 5 minutes. Then the patients were 
transferred to the post-anesthetic care unit (PACU). When pa-
tients requested to receive rescue analgesics and the postop-
erative pain score assessed using a visual analogue scale was 
above 5 points, fentanyl 1 μg/kg was administered. 
The primary outcome was a coughing response, which was 
evaluated during the recovery period from the time of aware-
ness to 5 minutes after extubation. Coughing severity was 
classified using the 3-point scale described by Minogue, et al.:5 
1=mild (single) cough, 2=moderate (≤5 s) cough, and 3=se-
vere (>5 s) cough. Grades 2 and 3 were considered clinically 
deleterious. MAP and heart rate values were recorded 5 min-
utes before the end of surgery (T1), at the end of surgery (T2), 
at the point of awareness (T3), at the point of extubation (T4), 
2 minutes after extubation (T5), 5 minutes after extubation (T6), 
at admission to the PACU (T7), and 10 minutes after admission 
to the PACU (T8). The respiration rate and sedation were re-
corded at T5, T6, T7, and T8. Sedation was classified using a 
4-point scale: 0=sleepy and not arousable, 1= sleepy yet arous-
able, 2=drowsy, and 3=alert.18 Time to awareness (from the 
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end of the surgery to eyes opening) and time to extubation 
(from the end of the surgery to extubation) were also recorded 
and compared. Postoperative pain score, consumption of an-
algesics, PONV, and any adverse events at the PACU were re-
corded.
We calculated the sample size based on the previous finding 
that 1.5 ng/mL of remifentanil suppressed coughing in 69% of 
patients under sevoflurane-remifentanil anesthesia7 and that 
a difference in the incidence of at least 30% would be clinically 
relevant. Thus, 31 patients per group were required based on 
α=0.05. Assuming a loss of follow-up of 20% of the patients, a 
total sample size of 74 was needed to achieve 80% power. Sta-
tistical analyses were performed using the SAS software pack-
age, version 9.2 (SAS Institute Inc., Cary, NC, USA). Coughing 
incidence and severity were analyzed using the Mantel-Haen-
szel chi-squared test. After testing for normally distributed 
data using the Kolmogorov-Smirnov test and Shapiro-Wilk test, 
continuous and categorical variables were analyzed using a 
two-sample t-test and a chi-squared test, respectively. The vari-
ables that did not show normal distribution were analyzed us-
ing a Mann-Whitney U test. Student’s t-test at each time point 
and a general linear mixed model were used when comparing 
changes in MAP, heart rate, and respiration rate between the 
two groups. The sedation scale was analyzed using a general-
ized estimating equation. A p value of <0.05 was considered 
statistically significant.
RESULTS
Of the 74 patients enrolled in this study, eight were excluded 
due to thiopental sodium administration for brain protection 
during temporary clipping, and two patients were withdrawn 
due to surgical bleeding. Therefore, 64 patients successfully 
completed the study, and their characteristics can be found in 
Table 1.
There were no significant differences between groups in 
terms of the incidence (p=0.14) and severity (p=0.39) of cough-
ing (Fig. 1). At the point of extubation, 18 patients (56.2%) in 
the dexmedetomidine group and 12 patients (37.5%) in the 
remifentanil group presented grade 2 coughs while two pa-
tients (6.3%) in the dexmedetomidine group and five patients 
(15.6%) in the remifentanil group presented grade 3 coughs. 
Fig. 2 shows the MAPs and heart rates of both groups over 
time. MAP (p=0.01) and heart rate (p=0.04 and 0.01, respec-
tively) at admission to PACU and after 10 minutes in the PACU 
Table 1. Patient Characteristics and Clinical Data
Remifentanil group (n=32) Dexmedetomidine group (n=32) p value
Age (yr) 55.8±7.1 56.5±5.8 0.67
Gender (M/F) 5/27 9/23 0.23
ASA classification (I/II) 12/20 14/18 0.61
Height (cm) 157.7±7.2 158.8±6.9 0.56
Weight (kg) 60.7±10.7 62.5±10.2 0.49
Anesthesia duration (min) 352±77 382±50 0.07
Postoperative pain (VAS) 5 (4) 4 (4) 0.57
Consumption of fentanyl (μg) 55±6 62±5 0.59
ASA, American Society of Anesthesiologists; VAS, visual analogue scale.
Values are mean±SD or median (IQR) or numbers. 
Fig. 1. Cough profile at the point of awareness (A) and extubation (B) for the dexmedetomidine group ( ) and remifentanil group ( ). Grade of cough: 0=no 
cough, 1=mild (single) cough, 2=moderate (≤5 s) cough, 3=severe (>5 s) cough. 
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were significantly higher in the remifentanil group than in the 
dexmedetomidine group. The respiration rate was significantly 
lower in the remifentanil group than in the dexmedetomidine 
group at 2 minutes (p<0.01) and 5 minutes (p<0.01) after extu-
bation (Fig. 3). The recovery profiles of both groups are shown 
in Table 2. There was no significant difference between the two 
groups in sedation score. Time to awareness in the dexmedeto-
midine group was longer than in the remifentanil group yet 
not statistically significant (p=0.05). Postoperative pain score 
(p=0.57) and consumption of analgesics (p=0.59) did not dif-
fer between the two groups. No adverse events occurred in ei-
ther group. 
DISCUSSION
In the present study, a single dose of dexmedetomidine was as 
effective as remifentanil TCI in attenuating airway reflex, hy-
pertension, and tachycardia during recovery from general an-
esthesia in patients undergoing clipping of an unruptured ce-
rebral aneurysm. In addition, such a dose did not appear to 
induce respiratory depression. The respiration rate was signif-
icantly higher in the dexmedetomidine group than in the remi-
fentanil group at 2 and 5 minutes after extubation.
Rapid recovery of consciousness while maintaining hemo-
dynamic stability is considered more important for neurosur-
gery than any other surgical area. Therefore, various agents 
have been investigated to allow for smooth emergence after 
craniotomy. Previous studies demonstrated that remifentanil 
can be useful based on its sensitive half-time, allowing for a 
more predictable emergence and recovery than other opiate 
agents.19-21 Therefore, we chose a Ce of 1.5 ng/mL, which is close 
to the EC50 of remifentanil in suppressing emergence cough,6 
and compared it to the antitussive effect of dexmedetomidine. 
Jun, et al.7 reported that 1.5 ng/mL of remifentanil effectively 
reduced emergence cough after sevoflurane-remifentanil an-
esthesia. The dexmedetomidine dose was based on a study that 
concluded that a single, 0.5 μg/kg of dose of dexmedetomi-
dine attenuates noxious stimuli when compared to a placebo 
group.11,22
Most sedatives, hypnotics, and analgesics suppress the stim-
ulatory effect of hypoxemia or hypercapnia on ventilation. Th-
erefore, excessive administration of these drugs can produce re-
spiratory depression, which significantly exacerbates hypoxia 
or CO2 retention. While hypoxia and hypercapnia can be dele-
terious in all surgical fields, it must be particularly avoided in 
patients with intracranial pathology, as events of hypoxia and 
hypercapnia may eventually lead to the aggravation of poor 
neurologic outcomes. Rapid recovery of consciousness is critical 
for the postoperative period after neurosurgery. Delayed emer-
gence could confuse the neurosurgeon and anesthesiologist. 
The recovery period after neurosurgery requires a special strat-
egy to ensure smooth emergence without respiratory depres-
sion and delayed sedation. 
There are many articles regarding sedation with dexmedeto-
Fig. 2. Changes in mean arterial pressure and heart rate during recovery for the dexmedetomidine group ( ) and remifentanil group ( ). *p<0.05 between 
groups. T1, 5 minutes before end of surgery; T2, at termination of sevoflurane; T3, at awareness; T4, at extubation; T5, 2 minutes after extubation; T6, 5 min-
utes after extubation; T7, at admission to PACU; T8, 10 minutes in PACU. PACU, post-anesthetic care unit. 
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midine that describe the distinctive qualities of sedation, which 
is similar to normal sleep. Particularly in intensive care units, 
dexmedetomidine induces sedation while allowing patients to 
interact and answer questions when stimulated yet return to 
tranquility and calmness when left alone.13,23 This unique char-
acteristic of sedation can allow for a smooth emergence from 
general anesthesia by blunting airway reflexes, agitation, and 
hemodynamic changes.
Hsu, et al.24 demonstrated that respiration changes occur dur-
ing remifentanil infusion, as the tidal volume does not increase 
enough to overcome the reduction of the respiration rate; as 
such, the decrease of minute ventilation can produce hyper-
capnia. On the other hand, the respiration pattern during dex-
medetomidine infusion is virtually unchanged. This preserved 
respiration is a unique advantage of the α-2 agonist that dis-
tinguishes it from other sedatives, hypnotics, and analgesics.24,25 
The present study showed that patients who were treated with 
dexmedetomidine maintained an appropriate respiration rate 
from extubation to 5 minutes thereafter, which supports the 
respiration property of dexmedetomidine.24 Even if the effects 
of remifentanil disappear rapidly, transiently depressed respi-
ration in the immediate postoperative period can occur and 
worsen the neurologic outcome.26 In patients with a higher risk 
of postoperative respiratory depression and in those who have 
undergone surgery and require extreme caution regarding re-
spiratory depression, administering dexmedetomidine is pref-
erable to opioid analgesics.12,27,28
In the recovery period after general anesthesia, dexmedeto-
midine can attenuate coughing reflex and prevent emergence 
agitation when compared with opiate agents.29,30 A recent study 
reported that an additional single dose (0.5 μg/kg) of dexme-
detomidine can attenuate emergence cough when compared 
with an infusion of low-dose remifentanil alone without delay-
ing recovery from general anesthesia. A single dose of dexme-
detomidine can help smooth emergence without respiratory 
depression and delayed sedation.22
As mentioned above, intravenous dexmedetomidine is ef-
fective in inhibiting hypertension and tachycardia during the 
perioperative period for neurosurgical patients. On the other 
hand, there are previous studies that have reported an increase 
of systemic arterial pressure in response to rapid intravenous 
administration of dexmedetomidine.31,32 This study, which in-
volved the administration of 0.5 μg/kg dexmedetomidine for 5 
minutes, did not result in an increase of blood pressure or the 
use of antihypertensive medications when compared to remi-
fentanil. When the patient was admitted to the PACU, MAP 
and heart rate were significantly lower in patients who received 
dexmedetomidine. Moreover, 10 minutes after admission to 
the PACU, heart rate was significantly lower in patients who 
received dexmedetomidine. This difference was statistically 
significant yet within the clinically acceptable range. 
The incidence of coughing in the present study was slightly 
higher than those of previous studies.7,8 We speculate that the 
difference in coughing response might have been due to the 
type of surgeries, features of patients, and recovery maneuvers 
during extubation. Furthermore, it might have also been due to 
applying coughing criteria strictly, as we considered even small 
movements of the head as coughing. Additionally, unneces-
sary deeper sedation with the purpose of suppressing cough-
ing could be dangerous for neurosurgical patients. Excessive 
sedation can disrupt prompt detection of neurologic change 
and induce hypoventilation and hypercapnia, and the neuro-
logic outcome can be worsened. Although the mechanism of 
the antitussive effect of dexmedetomidine is not clear in the 
previous studies, which evaluated the effects of dexmedeto-
midine in the recovery period after general anesthesia, the se-
dation property without respiratory depression may play a 
major role in the attenuation of the response related to extu-
bation. 
There were several limitations to this study. First, as the ex-
act data on hypoventilation or hypercapnia were not obtained 
during the recovery periods, it was not clear whether or not 
significant respiratory depression was present in the remifen-
tanil group. We previously demonstrated that most patients 
receiving a Ce of over 2 ng/mL of remifentanil showed hyper-
capnia (end tidal CO2 concentration >40 mm Hg) during an-
esthetic emergence.33 Although respiratory rate is not equiva-
lent to minute ventilation and it is not evident whether opioids 
induce clinically significant respiratory depression in neuro-
surgical patients, systemically administered opioids profound-
ly diminish the respiratory rate more so than the reduction of 
tidal volume, which may induce hypercapnia.34 Thus, remifen-
Table 2. Recovery Profiles
Remifentanil group (n=32) Dexmedetomidine group (n=32) p value
Awareness time (min) 6.6±2.8 7.9±2.2 0.05
Extubation time (min) 7.9±3 9.1±2.6 0.83
Sedation scale (0/1/2/3)
2 min after extubation 8/11/11/2 9/12/9/2 0.66
5 min after extubation 3/7/17/5 6/8/11/7 0.56
Admission to PACU 2/5/18/7 0/6/22/4 0.77
10 min in PACU 1/7/24/0 1/4/27/0 0.37
PACU, post-anesthetic care unit.
Values are mean±SD or number. Grade of sedation, 0=sleepy with no arousal, 1=sleepy yet arousable, 2=drowsy, 3=alert.
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tanil administration can induce hypercapnia, and it may pres-
ent a potential risk in patients undergoing craniotomy. Second, 
remifentanil and dexmedetomidine are different agents with 
distinct mechanisms, and there is no existing research regard-
ing the optimal dexmedetomidine and remifentanil doses to 
suppress the airway reflexes after a craniotomy. Therefore, de-
termining reliable parameters for equipotent concentrations at 
each time is difficult. Residual effects of drugs that affect airway 
reflexes determine the extent of the coughing response before 
and after extubation. However, in this study, there were no dif-
ferences between groups in terms of end-tidal sevoflurane con-
centration. In patients treated with a single bolus of dexme-
detomidine, the Ce of remifentanil was so low that it could not 
play any clinical role. 
In conclusion, a single bolus of dexmedetomidine and remi-
fentanil TCI have equal effectiveness in attenuating airway re-
flexes and hemodynamic changes in patients undergoing ce-
rebral aneurysm clipping, although better preservation of 
respiration was observed in the dexmedetomidine group.
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